Medscape. May 09, 2013
The American Urological Association (AUA) has issued a new guideline for the management of castration-resistant prostate cancer (CRPC) that provides a "rational basis" for treatment decisions.
Those decisions are now "complex" because a group of treatment
options for metastatic disease has emerged in a short period of time,
according to a press release issued at AUA 2013 Annual Scientific
Meeting, held in San Diego, California.
Read the full Medscape report
(Free sign-up may be required)
